Quris is developing a fully automated, self-training AI platform designed to better predict clinical safety and efficacy for new drug candidates.
The company is pioneering clinical trials on chips, which involves testing thousands of novel drug candidates on hundreds of stem-cells-derived “patients-on-a-chip”. Its fully automated, self-training AI platform is designed to accurately predict clinical safety and efficacy for novel drugs faster and more cost effectively than before – all while minimizing animal testing.
The Quris platform is being trained on known safe and toxic drugs, so it can then rapidly screen thousands of potential new drug formulations.
The company’s initial focus is on rare genetic diseases that can’t be modelled in animals. The first drug developed on the platform addresses Fragile-X Syndrome, a common inherited cause of autism. Quris’s Fragile-X drug is preparing for clinical testing in early 2022.
Dual-headquartered in Boston and Israel, the company recently made its public launch, along with the closing of a $9M seed round of funding. Quris is led by an experienced team, including Moderna co-founder Robert Langer, and Nobel Laureate Aaron Ciechanover.
Subscribe for alerts on new companies featured on Startups.Bio
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
